Evaluating the Efficacy of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer: Insights from the ASCENT Trial
The Ascent Trial, a global study, evaluated the efficacy and safety of sacituzumab govitecan as a second-line treatment for metastatic triple-negative breast cancer (mTNBC).
